PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma

被引：4

作者：

Guermazi, A.

Juweid, M. E.

机构：

[1] Synarc Inc, San Francisco, CA 94105 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

来源：

BRITISH JOURNAL OF RADIOLOGY | 2006年 / 79卷 / 941期

关键词：

D O I：

10.1259/bjr/31368041

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];

摘要：

引用

收藏

页码：365 / 367

页数：3

相关论文

共 11 条

[1]

Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma [J].

Allen-Auerbach, M ;

Quon, A ;

Weber, WA ;

Obrzut, S ;

Crawford, T ;

Silverman, DHS ;

Ratib, O ;

Phelps, ME ;

Czernin, J .

MOLECULAR IMAGING AND BIOLOGY, 2004, 6 (06) :411-416

[2]

Cheson BD, 2005, BLOOD, V106, p10A

[3]

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[4]

Fields PA, 2005, HAEMATOLOGICA, V90, P1711

[5]

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].

Jerusalem, G ;

Beguin, Y ;

Fassotte, MF ;

Najjar, F ;

Paulus, P ;

Rigo, P ;

Fillet, G .

BLOOD, 1999, 94 (02) :429-433

[6]

Jerusalem G, 2000, HAEMATOLOGICA, V85, P613

[7]

Role of positron emission tomography in lymphoma [J].

Juweid, ME ;

Cheson, BD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4577-4580

[8]

Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography [J].

Juweid, ME ;

Wiseman, GA ;

Vose, JM ;

Ritchie, JM ;

Menda, Y ;

Wooldridge, JE ;

Mottaghy, FM ;

Rohren, EM ;

Blumstein, NM ;

Stolpen, A ;

Link, BK ;

Reske, SN ;

Graham, MM ;

Cheson, BD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4652-4661

[9]

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma [J].

Naumann, R ;

Vaic, A ;

Beuthien-Baumann, B ;

Bredow, J ;

Kropp, J ;

Kittner, T ;

Franke, WG ;

Ehninger, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :793-800

[10]

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma:: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? [J].

Spaepen, K ;

Stroobants, S ;

Dupont, P ;

Van Steenweghen, S ;

Thomas, J ;

Vandenberghe, P ;

Vanuytsel, L ;

Bormans, G ;

Balzarini, J ;

De Wolf-Peeters, C ;

Mortelmans, L ;

Verhoef, G .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :414-419